Ignite Creation Date:
2024-05-05 @ 6:30 PM
Last Modification Date:
2024-10-26 @ 9:34 AM
Study NCT ID:
NCT00491504
Status:
COMPLETED
Last Update Posted:
2022-02-09
First Post:
2007-06-25
Brief Title:
This Study Contains an Active Drug Treatment Group With Mometasone Furoate Nasal Spray and a Placebo Dummy Treatment Group for Seasonal Allergic Rhinitis SAR Study P05073COMPLETED
Sponsor:
Organon and Co
Organization:
Organon and Co
Study Overview
Official Title:
A Double-Blind Placebo-Controlled Randomized Parallel-Group Study Using Subjective and Objective Measures to Evaluate the Clinical Efficacy of Mometasone Furoate Nasal Spray MFNS Following Initial and Maintenance Dosing in Subjects With Allergen-Induced Seasonal Allergic Rhinitis SAR in an Environmental Exposure Chamber EEC
Status:
COMPLETED
Status Verified Date:
2022-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate how well mometasone furoate nasal spray MFNS works to relieve SAR symptoms compared to Placebo when symptoms are induced in a chamber setting Evaluation will be based on subjects self-assessed nose symptoms Other areas the study will evaluate are 1 changes in eye symptoms ocular symptom severity score after dosing 2 how long MFNS works in relieving the nose nasal and eye ocular symptoms after 7 daily doses 3 measurements of nose nasal blockage obstruction and 4 measurements of the subjects opinion of the study drugs by asking different questions This study is could last up to 53 days for some subjects
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None